GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
---|
GLRX3 | 15987 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Proteomics and qRT-PCR and Western Blotting | Up | 0.56 | 0.0032 | 34794402
|
SOX2 | 11195 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | qRT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.5695 | 29130098
|
CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by IF staining and qRT-PCR | NA | 0.44 | 0.456 | 27891685
|
CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 34794402
|
CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | FACs followed by SFA | NA | 0.44 | 0.456 | 26284537
|
CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | FACs followed by SFA | NA | 0.44 | 0.456 | 27748818
|
CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | FACs followed by SFA | NA | 0.44 | 0.456 | 27748818
|
CD24 | 1645 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by FACs | NA | 0.44 | 0.456 | 26284537
|
PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by IF staining and qRT-PCR | NA | 0.44 | 0.7582 | 27891685
|
PROM1 | 9454 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | FACs followed by SFA | NA | 0.44 | 0.7582 | 26284537
|
STAT3 | 11364 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA and Western Blotting | NA | 0.28 | 0.0223 | 27748818
|
ZG16B | 30456 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0021 | 29100320
|
MIR100 | 31487 | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0032 | 21785383
|
MIR106A | 31494 | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 21785383
|
MIR125B1 | 31506 | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0042 | 21785383
|
MIR192 | 31562 | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0021 | 21785383
|
MIR429 | 13784 | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0042 | 21785383
|
MIR99A | 31650 | HTM/LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics and qRT-PCR | Down | 0.24 | 0.0021 | 21785383
|
CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | CFA followed by IF staining | NA | 0.24 | 1 | 30395429
|
CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by IF staining | NA | 0.24 | 1 | 27891685
|
CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by FACs | NA | 0.24 | 1 | 34794402
|
CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | Gemcitabine | CFA followed by SFA and FACs | NA | 0.24 | 1 | 19598259
|
CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | FACs followed by SFA | NA | 0.24 | 1 | 27748818
|
CD44 | 1681 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | FACs followed by SFA | NA | 0.24 | 1 | 27748818
|
CXCR4 | 2561 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | CFA followed by IF staining | NA | 0.24 | 0.0498 | 30395429
|
CXCR4 | 2561 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | Migration and Invasion assay followed by qRT-PCR | NA | 0.24 | 0.0498 | 23592398
|
EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by IF staining | NA | 0.24 | 0.211 | 27891685
|
EPCAM | 11529 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by FACs | NA | 0.24 | 0.211 | 34794402
|
POU5F1 | 9221 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | CFA followed by IF staining | NA | 0.24 | 0.6448 | 30395429
|
ALDH1A1 | 402 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Proteomics | Up | 0.2 | 0.684 | 34794402
|
ABCB1 | 40 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | Gemcitabine | CFA followed by SFA and qRT-PCR | NA | 0.2 | 0.0604 | 19598259
|
ABCC1 | 51 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | Gemcitabine | CFA followed by SFA and qRT-PCR | NA | 0.2 | 0.0212 | 19598259
|
ABCG2 | 74 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | Gemcitabine | CFA followed by SFA and qRT-PCR | NA | 0.2 | 0.1739 | 19598259
|
ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.684 | 27891685
|
ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | ALDEFLUOR assay followed by SFA | NA | 0.2 | 0.684 | 27748818
|
ALDH1A1 | 402 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | FACs followed by SFA | NA | 0.2 | 0.684 | 27748818
|
MET | 7029 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | Migration and Invasion assay followed by qRT-PCR | NA | 0.2 | 0.0191 | 23592398
|
NANOG | 20857 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.5461 | 27891685
|
SOX9 | 11204 | LTM | Pancreatic Cancer | Adenocarcinoma | HPAC | Gemcitabine | Migration and Invasion assay followed by qRT-PCR and SFA | NA | 0.2 | 0.0244 | 23592398
|
AGPAT4 | 20885 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34794402
|
AKR1C3 | 386 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34794402
|
CTSD | 2529 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 34794402
|
DYNC1I1 | 2963 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34794402
|
FMNL2 | 18267 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34794402
|
GAPDH | 4141 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 34794402
|
GLRX | 4330 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34794402
|
HSP90AA1 | 5253 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Proteomics | Up | 0.08 | 0.0064 | 34794402
|
HSP90AB1 | 5258 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Proteomics | Up | 0.08 | 0.0074 | 34794402
|
HSP90B1 | 12028 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34794402
|
HSPA5 | 5238 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Proteomics | Up | 0.08 | 0.0117 | 34794402
|
HSPA5 | 5238 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Proteomics | Up | 0.08 | 0.0117 | 34794402
|
HSPB1 | 5246 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 34794402
|
KRT1 | 6412 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34794402
|
KRT9 | 6447 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Proteomics | Up | 0.08 | 0.0042 | 34794402
|
PIK3CA | 8975 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Proteomics | Up | 0.08 | 0.0032 | 34794402
|
TF | 11740 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Proteomics | Up | 0.08 | 0.0021 | 34794402
|
TIMP1 | 11820 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Proteomics | Up | 0.08 | 0.0053 | 34794402
|
TP11 | NA | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34794402
|
TUBB3 | 20772 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Proteomics | Up | 0.08 | 0.0011 | 34794402
|
VIM | 12692 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Proteomics | Up | 0.08 | 0.017 | 34794402
|
MIR142 | 31529 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 21785383
|
MIR154 | 31541 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 21785383
|
MIR155 | 31542 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 21785383
|
MIR15B | 31544 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0085 | 21785383
|
MIR195 | 31566 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 21785383
|
MIR19A | 31574 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 21785383
|
MIR29A | 31616 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 21785383
|
MIR29B1 | 31619 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 21785383
|
MIR302d | 31765 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 21785383
|
MIR373 | 31787 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 21785383
|
MIR384 | 31878 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 21785383
|
MIR424 | 31881 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0064 | 21785383
|
MIR448 | 26069 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 21785383
|
MIR485 | 32067 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 21785383
|
MIR489 | 32074 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 21785383
|
MIR497 | 32088 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 21785383
|
MIR498 | 32092 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 21785383
|
MIR512-1 | 32090 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 21785383
|
MIR517B | 32115 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 21785383
|
MIR518e | 32119 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 21785383
|
MIR526B | 32100 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 21785383
|
MIR549A | 32803 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 21785383
|
MIR551A | 32806 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 21785383
|
MIR559 | 32815 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 21785383
|
MIR575 | 32831 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 21785383
|
MIR599 | 32855 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 21785383
|
MIR625 | 32881 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 21785383
|
MIR630 | 32886 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 21785383
|
MIR641 | 32897 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 21785383
|
MIR645 | 32901 | HTM | Pancreatic Cancer | Adenocarcinoma | HPAC | NA | SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 21785383
|